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Figure 1: 2SL breakdown reaction. 2SL acts 
on 2SNAC to produce fumarate and NAC. This 
reaction is reversible. 
BACKGROUND
1. Succination is a contributor to pathogenesis 
in diabetes, obesity, and certain cancers 10-13
2. Succination forms the oncometabolite 
S-(2-succino)cysteine lyase (2SC)1,2 
3. A breakdown pathway for 2SC is encoded by the 
yxe operon (Fig. 1). In Enterococcus italicus and 
Dickeya dadantii this operon includes the enzyme 
2SL, a protein that acts on 2SNAC.15
4. 3D Modeling 2SL (Fig. 2)
(i) We created a 3D model of 2SL and its four active 
sites (using the the known crystal structure of 
Fumarate lyase from Mesorhizobium)
(ii) By comparing 2SL to related enzymes, we made 
predictions about which residues are functional 
significant to 2SL  (including residue N13)
METHODS
Figure 2: The Dickeya dadantii 2SL 
model. Sequences were run through 
https://swissmodel.expasy.org/. A 
model was produced using the known 
crystal structure of Fumarate lyase from 
Mesorhizobium (right). The homologous 
residues of active sites on three 
different lyase I-like enzymes were 
marked on the 2SL models (left).
Next steps will look like repeating the HPLC assays for the forward 
direction. Then, we will kinetically characterize  the mutant enzyme. This 
will give us further experimental evidence that the N13 residue is 
functionally significant to 2SL activity. Finally, we will repeat the process 
with more mutants by altering different 2SL residues. This information 
could aid in a broader search for 2SL enzymes and  2SC breakdown 
pathways throughout  other kingdoms. The identification of more 2SC 
catabolic pathways will contribute insight to the ongoing efforts to 
understand and treat diseases such as diabetes, obesity, and cancer. 
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5. Site-Directed Mutagenesis 
Using primers with a mismatch at position 13, we 
introduced a mutation converting polar asparagine to 
non-polar isoleucine (N13I). Then, we treated the PCR 
product with Dpn1 to digest the methylated template 
DNA.
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7. HPLC Assays
The reactions were run at 37℃ for one 
minute before they were stopped. 
Assays used a mobile phase of 0.1% 
TFA and 3% acetonitrile. The retention 
times are 6 minutes for fumarate, 8 for 
NAC, and 10 for 2SNAC.
 
a) The forward reaction assays 
produced peaks of heights 1.5 
(fumarate), 1.7 (NAC), and 522.4 
(2SNAC) for the WT enzyme. Peak 
heights for the N13I mutant were 9.4 
(fumarate), 1.8 (NAC), and 532.1 
(2SNAC).
b) The reverse reaction assays produced 
peaks of area 11197.5(fumarate), 
4872.8(NAC), and 6998.4 (2SNAC) for 
the WT enzyme. Peak areas for the N13I 
mutant were 7127.3 (fumarate), 2583.4 
(NAC), and 9251.5 (2SNAC).
6. SDS-PAGE gel of WT and mutant 2SL 
We were able to express and purify both 
mutant and WT 2SL N-terminal 
HIs-tagged  proteins to near 
homogeneity. Proteins were purified 
using nickel chromatography. Target 
proteins are 52 kDa. 
RESULTS DISCUSSION
The HPLC assay of the reverse reaction seems to suggest that the 
mutant N13I enzyme is more efficient (product peak area = 9251.5) than 
the WT (product peak area = 6998.4), at least in the reverse direction. 
This trend seemed to hold true through multiple trials of the assay. 
The disparity between the product peaks in the forward reaction was 
smaller. Upon a second HPLC assay, the results of the forward reaction 
were not replicated. 
Only one run of the HPLC assay is shown, more assays will need to be 
done in the forward direction  to determine whether the results are 
conclusive. 
